The global Urinalysis Market is growing steadily as healthcare providers increase the use of automated urine testing, AI-enabled diagnostics, and point-of-care testing solutions for early disease detection. Rising cases of kidney disease, urinary tract infections, diabetes, and other chronic disorders are strengthening demand across hospitals, clinical laboratories, home care, and research settings.

Market Highlights

• Market Size (2025): USD 4.43 billion
• Market Size (2026): USD 4.76 billion
• CAGR (2026–2034): 7.53%
• Forecast Year: 2034
• Projected Market Size (2034): USD 8.52 billion
• Dominant Region: North America
• Fastest Growing Region: Asia Pacific

Market Overview

Urinalysis is a widely used diagnostic method for detecting and monitoring diseases through urine samples. It helps identify biomarkers such as glucose, protein, ketones, bilirubin, pH levels, cells, crystals, and microorganisms.

The market is benefiting from automated analyzers, digital reporting, AI-based interpretation, and growing use of urine testing in preventive healthcare. Hospitals, laboratories, clinics, and wellness centers are increasingly adopting advanced urinalysis systems to improve speed, accuracy, and workflow efficiency.

Growth Drivers

The rising prevalence of kidney and urinary tract diseases is a major growth driver. Chronic kidney disease, urinary tract infections, diabetes, and metabolic disorders require regular screening, making urinalysis an essential diagnostic tool.

Increasing awareness about early disease detection is also supporting market expansion. Preventive healthcare programs, routine check-ups, and chronic disease monitoring are boosting demand for urinalysis products and services.

Market Challenges

The high cost of advanced urinalysis instruments remains a major restraint, especially in low- and middle-income regions. Automated analyzers, reagents, calibration, maintenance, and integration with digital systems require significant investment.

Smaller clinics and rural healthcare facilities may continue relying on manual or semi-automated systems due to budget limitations.

Market Opportunities

The growing use of point-of-care testing kits is creating strong opportunities. POCT urinalysis solutions provide quick results at clinics, emergency rooms, primary care centers, and rural healthcare settings.

AI-based urinalysis tools are also opening new growth avenues by improving diagnostic accuracy, reducing human error, and enabling faster clinical decisions.

Segment Analysis

By product, consumables dominate the market due to frequent use of dipsticks, reagents, and disposables in both manual and automated urinalysis.

By test type, biochemical urinalysis holds a major share because it offers fast detection of glucose, protein, ketones, bilirubin, and pH levels.

By application, disease screening dominates the market due to rising use of urinalysis for UTIs, kidney disease, diabetes, and routine health monitoring.

By end-user, hospitals represent the largest segment due to high diagnostic test volumes, advanced infrastructure, and strong patient inflow.

Regional Analysis

North America leads the global urinalysis market due to advanced healthcare infrastructure, high awareness of chronic diseases, strong diagnostic adoption, and the presence of major market players.

Asia Pacific is expected to grow at the fastest pace, supported by rising healthcare spending, expanding diagnostic infrastructure, growing diabetes and kidney disease cases, and increasing adoption of affordable POCT solutions.

Europe also holds a significant share due to preventive healthcare initiatives, aging populations, strong reimbursement support, and wider use of automated urinalysis platforms.

Competitive Landscape

Key companies are focusing on automation, AI integration, portable testing devices, product portfolio expansion, and cloud-based diagnostic data management.

Key Companies

• Siemens Healthineers
• Hoffmann-La Roche Ltd
• Abbott Laboratories
• Beckman Coulter Inc.
• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• ARKRAY Inc.
• 77 Elektronika Kft.
• Thermo Fisher Scientific Inc.
• Mindray Medical International Limited

Recent Developments

In June 2025, PanGIA Biotech reported clinical trial data for its AI-driven urine test designed to detect early-stage prostate cancer non-invasively.

In April 2025, Fujirebio’s subsidiary Fluxus received a two-year grant of around USD 4.5 million from the GHIT Fund to develop an ultrasensitive point-of-care urine assay for tuberculosis diagnosis.

Click to Read the Complete Insights & Report:https://straitsresearch.com/report/urinalysis-market

Future Outlook

The urinalysis market is expected to grow steadily as diagnostic systems become faster, more automated, and increasingly connected with digital healthcare platforms. AI-powered tools, POCT kits, portable analyzers, and non-invasive urine-based testing will shape future market growth. Companies offering accurate, affordable, and easy-to-use urinalysis solutions are expected to gain a strong competitive advantage.

About Straits Research

Straits Research is a global market intelligence and consulting company that provides industry research, market forecasts, competitive analysis, and strategic insights across diverse sectors. The company helps businesses understand emerging trends, evaluate growth opportunities, and make informed decisions in competitive global markets.